作者
Yulong Li,Zhi Lv,Rong Ye,Yulong Dai,Liuzhenxiong Yu,Pingping Liu,Jinying Han,Yuqian Zhan,Lu Fang,Xin Chen,Huayan Chen,Jun Wu,Jingjing Cheng,Minhao Zhu,Zhengfei Qi,Lin Zhang,Kai Wang,Panpan Hu
摘要
Background: Parkinson's disease (PD) represents a prevalent neurodegenerative condition that leads to significant disability and contributes to a growing public health challenge worldwide. However, a comprehensive report on progress from 1990 to 2021 is still lacking, especially regarding the risk factors associated with PD by gender and age. This study aims to examine the patterns of PD incidence, mortality rates, and disability-adjusted life years (DALYs) across all age groups, along with the risk factors linked to PD-related fatalities, spanning the years from 1990 to 2021.Methods: We retrieved data on PD from the Global Burden of Disease Study 2021. The burden of PD was assessed using incidence, deaths, and disability-adjusted life-years (DALYs), with corresponding 95% confidence intervals (UIs). Analyses were conducted globally, regionally, and nationally for the period between 1990 and 2021, stratified by age, sex, and the Socio-demographic Index (SDI). Estimated annual percentage changes (EAPCs) were calculated to assess temporal trends. Only cases directly attributable to PD were included, and a comorbidity correction was applied to ensure accurate estimation of the burden.Findings: Globally, an estimated 13.35 million (95% UI, 12.67–14.08) individuals were living with PD in 2021, accounting for a 220% increase (95% UI, 210%–229%) in cases from 1990 to 2021. PD deaths increased from 148,068 (95% UI, 135,802–158,149) in 1990 to 388,194 (95% UI, 347,250–417,388) in 2021, while global disability-adjusted life years (DALYs) attributed to PD rose from 53.51 (95% UI, 49.54–57.56) to 94.68 (95% UI, 85.37–103.11) per 100,000 population during the same period. Age-standardized incidence rates increased from 7.82 (95% UI, 6.95–8.75) to 16.92 (95% UI, 15.16–18.82) per 100,000 population, and age-standardized mortality rates rose from 2.78 (95% UI, 2.55–2.97) to 4.91 (95% UI, 4.40–5.29) per 100,000 population. Among the five Socio-demographic Index (SDI) regions, the high SDI region reported the highest all-age PD-associated mortality rate in 2021, while East Asia showed the largest increase in incidence, with an estimated annual percentage change (EAPC) of 5.15 (95% CI, 5.09–5.21). The burden of PD was most pronounced in elder populations, with the 85–89 age group experiencing the highest incidence rate (417.62 per 100,000 population; 95% UI, 296.68–571.56), mortality rate (427.65 per 100,000 population; 95% UI, 350.74–473.70), and DALYs (4262.54 per 100,000 population; 95% UI, 3721.44–4681.33). Among 204 countries, Germany recorded the highest national incidence of PD in 2021 (53 per 100,000 population; 95% UI, 51–55), while Monaco had the highest mortality rate (20.41 per 100,000 population; 95% UI, 15.54–25.48) and the highest DALY rate (333.13 per 100,000 population; 95% UI, 267.52–396.18).Globally, smoking was a key risk factor for PD-associated mortality in 2021. Among different age groups, the proportion of deaths attributable to smoking ranged from -9.09% in individuals aged 50–54 years to -2.69% in those aged 95 years and elder.Interpretation: PD represents a significant and escalating global health challenge, driven by increasing incidence rates and an aging population. This growing burden highlights the urgent need for effective strategies in prevention, early diagnosis, and tailored management, particularly for elder males who are disproportionately affected. Addressing modifiable risk factors and advancing etiological research are crucial to mitigating the rising prevalence and optimizing resource allocation. Coordinated public health interventions and robust healthcare policies are essential to reduce the global impact of PD and improve outcomes for affected individuals.Funding: This work was supported by the National Natural Science Foundation of China, Grant/Award Numbers: 82471271, 82171917, 81971689, 82090034.Declaration of Interest: The authors declare no conflict of interest.